Insider Selling: Moderna (NASDAQ:MRNA) President Sells $5,883,845.67 in Stock

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 40,281 shares of the stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $146.07, for a total transaction of $5,883,845.67. Following the transaction, the president directly owned 1,562,029 shares in the company, valued at approximately $228,165,576.03. This represents a 2.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stephen Hoge also recently made the following trade(s):

• On Monday, September 14th, Stephen Hoge sold 40,294 shares of Moderna stock. The shares were sold at an average price of $144.13, for a total transaction of $5,807,574.22.

Moderna Stock Up 1.3%

Shares of NASDAQ MRNA traded up $1.85 during trading on Wednesday, hitting $145.62. 8,795,681 shares of the company traded hands, compared to its average volume of 11,582,703. The business’s fifty day moving average is $94.93 and its 200 day moving average is $68.18. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $176.66. The firm has a market capitalization of $58.14 billion, a price-to-earnings ratio of -18.23 and a beta of 1.10. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29.

Moderna (NASDAQ:MRNA) last issued its earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, beating the consensus estimate of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The company had revenue of $145.00 million during the quarter, compared to the consensus estimate of $102.93 million. During the same period last year, the business posted ($2.13) EPS. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. Equities research analysts predict that Moderna, Inc. will post -6.09 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Piper Sandler restated an “overweight” rating on shares of Moderna in a report on Monday, August 3rd. JPMorgan Chase & Co. increased their target price on Moderna from $40.00 to $77.00 and gave the stock an “underweight” rating in a report on Friday, August 21st. Deutsche Bank Aktiengesellschaft started coverage on shares of Moderna in a research report on Friday, August 28th. They issued a “hold” rating for the company. Wolfe Research upgraded shares of Moderna from an “underperform” rating to a “peer perform” rating in a report on Tuesday, August 25th. Finally, Jefferies Financial Group reaffirmed a “hold” rating on shares of Moderna in a research note on Wednesday, August 19th. Seven investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and five have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $76.72.

Hedge Funds Weigh In On Moderna

A number of hedge funds have recently bought and sold shares of MRNA. TD Waterhouse Canada Inc. raised its stake in shares of Moderna by 2.6% during the second quarter. TD Waterhouse Canada Inc. now owns 3,388 shares of the company’s stock valued at $246,000 after acquiring an additional 85 shares in the last quarter. Assetmark Inc. grew its stake in Moderna by 35.1% in the first quarter. Assetmark Inc. now owns 801 shares of the company’s stock worth $41,000 after purchasing an additional 208 shares in the last quarter. New Mexico Educational Retirement Board grew its stake in Moderna by 1.9% in the fourth quarter. New Mexico Educational Retirement Board now owns 15,700 shares of the company’s stock worth $463,000 after purchasing an additional 300 shares in the last quarter. IFP Advisors Inc increased its holdings in Moderna by 5.4% during the 4th quarter. IFP Advisors Inc now owns 6,785 shares of the company’s stock worth $200,000 after purchasing an additional 348 shares during the period. Finally, Deseret Mutual Benefit Administrators raised its position in Moderna by 16.9% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 2,640 shares of the company’s stock valued at $78,000 after purchasing an additional 382 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

About Moderna

Moderna, Inc is a biotechnology company that develops messenger RNA (mRNA) medicines and vaccines. Its platform is designed to provide cells with instructions to produce proteins that may help prevent or treat infectious diseases, cancer and other medical conditions.

The company’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. Moderna also maintains a pipeline of investigational programs in areas such as seasonal influenza, cytomegalovirus, oncology and rare diseases.

Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna serves markets in the United States and internationally through regulatory approvals, commercial partnerships and distribution arrangements.